Nitric oxide topical - NB Therapeutics
Alternative Names: gNOLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Theranox
- Developer NB Therapeutics
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Free radical scavengers; Nitric oxide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic wounds
- Discontinued Leg ulcer; Skin and soft tissue infections; Skin ulcer; Tinea pedis; Varicose ulcer
Most Recent Events
- 12 Jan 2011 No development reported - Phase-II for Chronic wounds in Canada (Topical)
- 05 Jan 2011 Nitric Bio is now called NB Therapeutics
- 14 Mar 2008 Nitric BioTherapeutics initiates enrolment in a second phase II trial for Varicose ulcer in the US